Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/22485
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMoles, Laura
dc.contributor.authorEscribano, Esperanza
dc.contributor.authorde Andrés, Javier
dc.contributor.authorMontes, María Teresa
dc.contributor.authorRodríguez, Juan M
dc.contributor.authorJiménez, Esther
dc.contributor.authorSáenz de Pipaón, Miguel
dc.contributor.authorEspinosa-Martos, Irene
dc.date.accessioned2019-06-28T13:39:29Z-
dc.date.available2019-06-28T13:39:29Z-
dc.date.issued2015
dc.identifier.citationJ Immunol Res.2015;(2015):538171
dc.identifier.urihttps://hdl.handle.net/20.500.12530/22485-
dc.description.abstractThe preterm infant gut has been described as immature and colonized by an aberrant microbiota. Therefore, the use of probiotics is an attractive practice in hospitals to try to reduce morbidity and mortality in this population. The objective of this pilot study was to elucidate if administration of two probiotic strains isolated from human milk to preterm infants led to their presence in feces. In addition, the evolution of a wide spectrum of immunological compounds, including the inflammatory biomarker calprotectin, in both blood and fecal samples was also assessed. For this purpose, five preterm infants received two daily doses (~10(9) CFU) of a 1:1 mixture of Bifidobacterium breve PS12929 and Lactobacillus salivarius PS12934. Bacterial growth was detected by culture-dependent techniques in all the fecal samples. The phylum Firmicutes dominated in nearly all fecal samples while L. salivarius PS12934 was detected in all the infants at numerous sample collection points and B. breve PS12929 appeared in five fecal samples. Finally, a noticeable decrease in the fecal calprotectin levels was observed along time.
dc.language.isoeng
dc.rightsopenAccess-
dc.subject.meshBiodiversity
dc.subject.meshCluster Analysis
dc.subject.meshFemale
dc.subject.meshGastrointestinal Microbiome
dc.subject.meshHumans
dc.subject.meshImmunity
dc.subject.meshInfant, Newborn
dc.subject.meshMilk, Human
dc.subject.meshPilot Projects
dc.subject.meshProbiotics
dc.subject.meshBifidobacterium
dc.subject.meshInfant, Extremely Low Birth Weight
dc.subject.meshInfant, Very Low Birth Weight
dc.subject.meshLactobacillus
dc.titleAdministration of Bifidobacterium breve PS12929 and Lactobacillus salivarius PS12934, two strains isolated from human milk, to very low and extremely low birth weight preterm infants: a pilot study.
dc.typeArtículo
dc.identifier.pubmedID25759843
dc.format.volume2015
dc.format.page538171
dc.identifier.e-issn2314-7156
dc.identifier.journalJournal of immunology research
dc.identifier.doi10.1155/2015/538171
dc.identifier.pmcPMC4352454
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. U. La Paz > Artículos
Hospitales > H. U. La Paz > Artículos

Files in This Item:
File Description SizeFormat 
PMC4352454.pdf861.61 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.